{"id":"focetria","safety":{"commonSideEffects":[{"rate":"10-40","effect":"Injection site reactions (pain, redness, swelling)"},{"rate":"5-15","effect":"Myalgia"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Fever"},{"rate":"5-10","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL6068361","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Focetria is a split-virion, inactivated influenza vaccine containing antigens from three influenza virus strains (trivalent formulation). It works by presenting viral antigens to the immune system, triggering both humoral (antibody) and cellular immune responses that provide protection against infection with the included influenza strains. The vaccine is administered intramuscularly and is designed to prevent seasonal influenza infection.","oneSentence":"Focetria is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against influenza virus strains.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:08.699Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children"}]},"trialDetails":[{"nctId":"NCT01032395","phase":"PHASE3","title":"Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus","status":"COMPLETED","sponsor":"Chiltern Pesquisa Clinica Ltda","startDate":"2010-03","conditions":"H1N1 Influenza Virus, Chronic Pulmonary Disease, Chronic Heart Disease","enrollment":342},{"nctId":"NCT01032408","phase":"PHASE3","title":"Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection","status":"COMPLETED","sponsor":"Chiltern Pesquisa Clinica Ltda","startDate":"2010-04","conditions":"H1N1 Influenza Virus, Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":154},{"nctId":"NCT01031966","phase":"PHASE2","title":"A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine","status":"COMPLETED","sponsor":"sigma-tau i.f.r. S.p.A.","startDate":"2009-11","conditions":"END STAGE RENAL DISEASE","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Focetria®","genericName":"Focetria®","companyName":"Chiltern Pesquisa Clinica Ltda","companyId":"chiltern-pesquisa-clinica-ltda","modality":"Biologic","firstApprovalDate":"","aiSummary":"Focetria is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against influenza virus strains. Used for Seasonal influenza prevention in adults and children.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}